Novartis Pursues ‘Invented In China’ Goal At New Shanghai Hub
This article was originally published in PharmAsia News
Executive Summary
Helped by Shanghai’s supportive policies to attract talent to back its transformation into a global innovation center by 2030, Novartis recently opened its global third-largest R&D center in the city, as part of a strategy to develop new compounds locally for the worldwide market by tapping into local expertise.